TeleCareSpot vs Willow
Two GLP-1 desks, one scoreboard. We put TeleCareSpot and Willow head-to-head on the published Brief Score — the same six factors, scored the same way.
TeleCareSpot
The verdict
TeleCareSpot takes this head-to-head.
TeleCareSpot scores 85 to 66 on our six-factor Brief Score — A nationwide desk with an oral option — full-formulary, but priced at the premium end.
That doesn't make Willow a bad call — it's best for readers who want mainstream telehealth glp-1 access. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| TeleCareSpot | Willow | |
|---|---|---|
| Brief Score | 85/100 (B) | 66/100 (C) |
| Semaglutide | $299/mo | From $299/mo (starting dose, compounded) |
| Tirzepatide | $399/mo | From $399/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
TeleCareSpot: $299 sema / $399 tirz nationwide, with an oral route.
Willow: New to the tracker on 1 August 2026. The published line reads From $299/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.